It would appear from the Bioshares report that TIS may now go to the 'top of the class'!
If Shire Pharmaceuticals paid $750M for a product that has now fallen short of expectations - well the end point for TIS in my opinion looks excellent.
Not too sure that a 500 person trial will show anything different to what has already been achieved.
The 'commercial partner' is scheduled to be announced before the end of this quarter.
I wait with strong anticipation!!
Regards...............
TIS Price at posting:
47.0¢ Sentiment: Hold Disclosure: Held
